Assessment and Tracking of Long-term Alefacept (LFA-3/IgG1 Fusion Protein) Safety (ATLAS)
Assessment and Tracking of Long-term Alefacept (LFA-3/IgG1 Fusion Protein) Safety (ATLAS)
Subjects exposed to alefacept are to be enrolled. Subjects will be contacted every 6 months to gather general health information.
There are no study-mandated tests, visits or clinical interventions after the 1st (enrolling) visit. After the patient is enrolled in the study, they will be contacted every 6 months to complete structured telephone interviews conducted by the ATLAS Study Center.
Inclusion Criteria:
Fremont, California 94538, United States
Fremont, California 94538, United States
LaGrange Highlands, Illinois 60525, United States
Grand Rapids, Michigan 49503, United States
Winnepeg, Manitoba R3C 0N2, Canada
North York, Ontario M3K 1Z1, Canada